@inproceedings{sesques:hal-04344759,
TITLE = {Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study},
AUTHOR = {Sesques, Pierre and Houot, Roch and Al Tabaa, Yassine and Le Bras, Fabien and Ysebaert, Loic and Jardin, Fabrice and Choquet, Sylvain and Bay, Jacques-Olivier and Gros, Fran{\c c}ois-Xavier and Morschhauser, Franck and Casasnovas, Olivier and Gastinne, Thomas and Thieblemont, Catherine and Joris, Magalie and Ricard, Laure and R{\'e}gny, Caroline and La Rochelle, Laurianne Drieu and Feugier, Pierre and Mar{\c c}ais, Ambroise and Tarte, Karin and Laurent, Camille and Cartron, Guillaume},
URL = {https://hal.science/hal-04344759},
BOOK
TITLE = {65th ASH Annual Meeting},
ADDRESS = {San Diego, United States},
VOLUME = {142},
NUMBER = {Supplement 1},
PAGES = {893},
YEAR = {2023},
MONTH = Dec, DOI = {10.1182/blood-2023-177703},
KEYWORDS = {Medicine ; Clinical endpoint ; Internal medicine ; Hazard ratio ; Cohort ; Diffuse large B-cell lymphoma ; Obinutuzumab ; Lymphoma ; Oncology ; Gastroenterology ; Rituximab ; Clinical trial ; Confidence interval},
HAL_ID = {hal-04344759},
HAL_VERSION = {v1},
}